Highlights Syngene International Limited Bombay S.E.

Equities

SYNGENE

INE398R01022

Market Closed - Bombay S.E. Other stock markets 06:01:20 2024-06-04 am EDT			5-day change	1st Jan Change
662 ^INR	-0.53%		-0.91%	-5.58%

Apr. 28	Syngene International Limited Submits an Appeal to the National Faceless Appeal Centre, for Assessment Year 2022-23	CI
Apr. 26	Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Syngene International Limited Recommends Final Dividend for the Financial Year 2024	Apr. 24	CI
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	Apr. 24	CI
Syngene International Limited Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 24	CI
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	Apr. 12	RE
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year	Mar. 14	CI
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	Feb. 27	RE
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit	Jan. 26	MT
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 25	CI
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion.	Nov. 30	CI
Syngene International's Consolidated Profit Jumps in Fiscal Q2; Shares Slump 7%	23-10-18	MT
Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-17	CI
Syngene International Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023	23-07-27	CI
Syngene International Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-26	CI
Syngene to Acquire Biologics Manufacturing Unit for $86 Million	23-07-05	MT
Syngene International Limited Announces the Acquisition of Unit 3 Biologics Manufacturing Facility in Bangalore, India, from Stelis Biopharma Limited	23-07-04	CI
Syngene International Limited agreed to acquire Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 7 billion.	23-07-03	CI
Syngene International Limited Recommends Special Additional Dividend	23-06-24	CI
INDIA STOCKS-Indian shares rise on earnings boost ahead of April derivatives expiry	23-04-27	RE
Syngene International Limited Recommends Special Dividend for the Financial Year 2023	23-04-26	CI
Syngene International Limited Recommends Final Dividend for the Financial Year 2023	23-04-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Syngene International Limited Bombay S.E.

Equities

SYNGENE

INE398R01022

Highlights

Filters